Drugs / contezolid acefosamil
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03747497 | Nov 2018 → Mar 2019 | gram-positive bacterial infections, skin disease caused by bacterial infection | MicuRx | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05369052 | May 2022 → Jun 2026 overdue | — | MicuRx | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | contezolid acefosamil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05369052 ↗ |
| Route | Intravenous | “IV and oral contezolid acefosamil given twice a day for 10 to 14 days” NCT03747497 ↗ |
| Route | Oral | “IV and oral contezolid acefosamil given twice a day for 10 to 14 days” NCT03747497 ↗ |